Therapeutic drug monitoring of vancomycin by AUCτ-MIC ratio in patients with chronic kidney disease

Ahmad Khoei , Rasool Soltani, Jaber Emami, Shirinsadat Badri , Shahram Taheri

Abstract


In this study which was conducted in Alzahra University Hospital (Isfahan, I.R. Iran), the therapeutic drug monitoring of vancomycin focused on determining area under the concentration-time curve at dosing interval (τ) at steady state/minimum inhibitory concentration (AUCτ/MIC) was carried out in chronic kidney disease (CKD) patients. The study population was selected from patients with the history of CKD (stages 3 or 4) treated by intravenous vancomycin. To determine vancomycin AUCτ, blood samples were taken at four different occasions (trough-1, peak, random, trough-2) between the fourth and fifth doses of vancomycin. Drug concentration was determined by fluorescence polarization technique, and the E-TEST technique was used to determine the MIC. Nineteen patients were included. For 8 (42%), 7 (37%), and 4 (21%) patients, trough concentration levels were found to be less than 10 mg/L, 10-20 mg/L, and more than 20 mg/L, respectively. The mean value of AUCτ for studied patients was 470.7 ± 228.3 mg.h/L and the mean MIC values was 1.04 ± 0.43 mg/L. Ten patients (53%) and 9 patients (47%) had the AUCτ/MIC ratios above 400 and below 400, respectively, with the average of 519.4 ± 391.3 h. Vancomycin dosing based on patient glomerular filtration rate (GFR), as a traditional method, is not accurate enough to gain the most desired vancomycin concentration in patients with decreased or changing kidney function. Measuring drug concentration and observing its therapeutic effects accordingly is inevitable in susceptible populations receiving vital drugs such as vancomycin.


Keywords


AUCτ/MIC; Chronic kidney disease; Therapeutic drug monitoring; Vancomycin.

Full Text:

PDF

References


Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1-10.

Ghiculescu RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. Aust Prescr. 2008;31(2):42-44.

McLawhon RW. Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics. In: Dasgupta A, editor. Therapeutic Drug Monitoring: Newer Drugs and Biomarkers. London: Academic Press; 2012. pp. 197-218.

Panwar B, Johnson VA, Patel M, Balkovetz DF. Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease. Am J Med Sci. 2013;345(5):396-399.

Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis. 1988;11(1):15-19.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325-327.

Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney Disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1-150.

Conil JM, Georges B, Breden A, Ruiz S, Cougot P, Fourcade O, et al. Estimation of glomerular filtration rate to adjust vancomycin dosage in critically ill patients: superiority of the Chronic Kidney Disease Epidemiology Collaboration equation? Anaesth Intensive Care. 2014;42(2):178-184.

Takahashi Y1, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, et al. Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin. J Infect Chemother. 2013;19(4):709-716.

COBAS INTEGRA® 400 plus. 2018. Available from: http://www.cobas.com/home/product/clinical-and-immunochemistry-testing/cobas-integra-400-plus.html.

The European Committee on Antimicrobial Susceptibility Testing. Media preparation for EUCAST disk diffusion testing and for determination of MIC values by the broth microdilution method. 2017. Available from: http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology/.

Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: one- versus two compartment Bayesian models. Ther Drug Monit. 1989;11(4):450-454.

Safarnavadeh T, Rezaee S, Dashti-Khavidaki S, Khalili H, Daneshjoo K, Sadrai S, et al. Steady-state pharmacokinetic analysis of vancomycin in Iranian pediatric patients. DARU. 2009;17(2):124-130.

Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020-3025.

Hsu CY, Ordoñez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74(1):101-107.

Ye ZK, Chen K, Chen YL, Zhai SD. A protocol for developing a clinical practice guideline for therapeutic drug monitoring of vancomycin. J Huazhong Univ Sci Technolog Med Sci. 2016;36(3):469-472.

Jin SJ, Yoon JH, Ahn BS, Chung JA, Song YG. Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing. Infect Chemother. 2014;46(1):21-29.

Oh SJ, Hong KS, Lee EJ, Choi HJ, Kong KA, Lee M, et al. Assessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines. Ann Lab Med. 2014;34(1):1-6.

Pondel J, Krajewski P, Królikowska N, Tobiasz A, Augustyniak-Bartosik H, Hurkacz M. Measurements of vancomycin concentrations in the blood - a method of personalization the antibiotic therapy in patients with chronic kidney disease. Pol Merkur Lekarski. 2017;42(250):145-150.

Golightly LK, Teitelbaum I, Kiser TH, Levin DA, Barber GR, Jones MA, et al., editors. Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. Aurora, United States: Springer Science; 2013. pp. 716.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.